about
Fasting enhances the response of glioma to chemo- and radiotherapyPhase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.Novel drugs in pediatric gliomas.Synthesis, biological evaluation, and structure-activity relationships of a novel class of apurinic/apyrimidinic endonuclease 1 inhibitors.Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survivalAntitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registriesMolecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.Molecular profiling of childhood cancer: Biomarkers and novel therapiesNew developments in the treatment of malignant gliomas.Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.TMZ-BioShuttle--a reformulated temozolomide.Circulating microRNAs as emerging non-invasive biomarkers for gliomas.Pregnenolone, a cholesterol metabolite, induces glioma cell apoptosis via activating extrinsic and intrinsic apoptotic pathwaysA microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker.Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry.Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).
P2860
Q27320014-C1AAEEA7-884A-45C4-BA07-87BA3C8C9BDBQ33401308-F18C1C7E-EC2C-4391-A733-B3397D00EA2EQ33685551-F36EA5EA-89BB-4995-B5C6-6E5C20D666AAQ34210627-5665CA46-59F0-40A9-A3F0-FF28CC4F9AC7Q34797919-83B8B3B8-D811-4454-9A7B-0EDF6484852FQ35196720-DDF8AFD0-593E-4049-B410-EC66220F5BEAQ35605776-110D2870-F0B6-4421-A90F-915E120F0836Q36159222-7E23488F-707F-49B8-8A3B-34060AF20AC3Q36250783-C528329E-379A-49BA-9E64-6B582F3F7E9DQ36972696-DA6AAB2B-2B94-42C3-92CC-69D301271986Q37118932-5A6EBADF-58E2-4A74-8E02-2F51AB95DC3BQ38891614-10C84258-F0E2-46FC-B776-862AB697065CQ39591407-2D4A710B-F8B2-4401-BC98-9C03DA642158Q39908784-F07938F5-3D84-4102-8A6F-DACF170723ECQ39939002-4D864790-3117-41C0-A368-3574E3A353E3Q41050204-5D792E65-FBC5-480E-B994-4BB09B345C56Q42720269-62304205-22C8-4937-AAB6-250534683FC2Q47998452-F8C5F821-C6A6-4989-9260-E349F1EE626AQ50071181-398C1E44-05F6-430A-B222-108A33589619Q55052526-AF04FC00-BEB0-40AD-8FCC-382900057354
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Temozolomide: a milestone in neuro-oncology and beyond?
@ast
Temozolomide: a milestone in neuro-oncology and beyond?
@en
type
label
Temozolomide: a milestone in neuro-oncology and beyond?
@ast
Temozolomide: a milestone in neuro-oncology and beyond?
@en
prefLabel
Temozolomide: a milestone in neuro-oncology and beyond?
@ast
Temozolomide: a milestone in neuro-oncology and beyond?
@en
P2860
P1476
Temozolomide: a milestone in neuro-oncology and beyond?
@en
P2093
Nicole Mutter
Roger Stupp
P2860
P304
P356
10.1586/14737140.6.8.1187
P577
2006-08-01T00:00:00Z